Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jung M, Kim SH, Hong S, Kang YA, Kim SK, Chang J, Rha SY, Kim JH, Kim DJ, Cho BC.

Yonsei Med J. 2012 Sep;53(5):931-9. doi: 10.3349/ymj.2012.53.5.931. Retraction in: Yonsei Med J. 2013 Jan 1;54(1):269.

2.

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, Chang J, Rha SY, Kim JH, Kim DJ, Cho BC.

Exp Ther Med. 2011 Jul;2(4):685-693. Epub 2011 May 12.

3.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

4.

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Jun;34(6):3205-10.

PMID:
24922695
5.

Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.

Szturmowicz M, Rudziński P, Kacprzak A, Langfort R, Bestry I, Broniarek-Samson B, Orłowski T.

Pneumonol Alergol Pol. 2014;82(5):422-9. doi: 10.5603/PiAP.2014.0055.

6.

Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.

Chen F, Luo X, Zhang J, Lu Y, Luo R.

Med Oncol. 2010 Sep;27(3):950-7. doi: 10.1007/s12032-009-9315-8. Epub 2009 Oct 15.

PMID:
19830603
7.

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.

J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.

PMID:
26573867
8.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
9.
10.

High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.

Duan X, Cui Y, Li H, Shi G, Wu B, Liu M, Chang D, Wang T, Kong Y.

Indian J Cancer. 2015 Dec;52 Suppl 3:E158-63. doi: 10.4103/0019-509X.186564.

11.
12.

Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.

Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H, Ichinose Y.

Eur J Cancer. 2005 Jun;41(9):1286-90.

PMID:
15939264
13.

Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.

Cho A, Hur J, Moon YW, Hong SR, Suh YJ, Kim YJ, Im DJ, Hong YJ, Lee HJ, Kim YJ, Shim HS, Lee JS, Kim JH, Choi BW.

BMC Cancer. 2016 Mar 16;16:224. doi: 10.1186/s12885-016-2251-z.

14.

CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.

Sone K, Oguri T, Nakao M, Kagawa Y, Kurowaka R, Furuta H, Fukuda S, Uemura T, Takakuwa O, Kanemitsu Y, Ohkubo H, Takemura M, Maeno K, Ito Y, Sato H, Muramatsu H, Niimi A.

Anticancer Res. 2017 Feb;37(2):935-939.

PMID:
28179355
16.

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.

Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.

Anticancer Res. 2013 Nov;33(11):5057-64.

PMID:
24222150
17.

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.

Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Review.

18.

Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.

Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, Barak V.

Anticancer Res. 1999 Jul-Aug;19(4C):3549-52.

PMID:
10629651
19.

Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.

Dogan I, Karyagar S, Karyagar SS, Kahraman C, Alver A.

Ann Nucl Med. 2014 Nov;28(9):829-35. doi: 10.1007/s12149-014-0877-y. Epub 2014 Jul 3.

PMID:
24990528
20.

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.

J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. Erratum in: J Clin Oncol. 2011 Dec 10;29(35):4725.

PMID:
21969500

Supplemental Content

Support Center